ARTEMIDE-01 study: preliminary results on efficacy and safety of rilvegostomig
Dr Mariana Brandão, medical oncologist at Jules Bordet Institut Brussels, summarizes the poster she presented.
Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01.
A novel approach to overcome resistance or enhancing the response to checkpoint inhibition involves the concurrent blockade of PD-1 and TIGIT receptors. Rilvegostomig has exhibited safety in non-small cell lung cancer (NSCLC) patients who have undergone prior checkpoint inhibitor (CPI) treatment, and initial efficacy outcomes warrant further investigation. Patient enrollment is still in progress.
With the educational support of:
 |  |  |  |  |